Detalhe da pesquisa
1.
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 35(1): 47-58, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27650277
2.
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923890
3.
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.
Transl Oncol
; 12(4): 597-601, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30695737
4.
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Mol Cancer Ther
; 14(2): 317-25, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25376610
5.
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Clin Cancer Res
; 21(5): 1002-9, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25501576